Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 9:38:100466.
doi: 10.1016/j.jbo.2022.100466. eCollection 2023 Feb.

Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment

Louren M Goedhart  1 , Vincent K Y Ho  2 , Joris J W Ploegmakers  1 , Ingrid C M van der Geest  3 , Michiel A J van de Sande  4 , Jos A Bramer  5 , Martin Stevens  1 , Paul C Jutte  1
Affiliations

Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment

Louren M Goedhart et al. J Bone Oncol. .

Abstract

Aim: Follow-up strategies for high-grade bone sarcomas have been optimized to facilitate early detection of local recurrence and distant metastasis. The ideology is that early detection enables early treatment presuming better survival. However, the clinical value for each individual patient remains questionable. This study aims to evaluate oncological events after initial treatment in order to assess current follow-up strategies for high-grade bone sarcomas in the Netherlands.

Patients and methods: A retrospective cohort study was conducted based on a national registry. All cases were retrieved from the Netherlands Cancer Registry. Our study consisted of 393 patients treated between 2007 and 2011 with complete follow-up data. Baseline characteristics were analysed for all entities. Local recurrence and distant metastasis was analysed along with overall survival for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and chordoma.

Results: Median follow-up was 8,3 years for high-grade chondrosarcoma, 4,9 for high-grade osteosarcoma, 3,8 for Ewing sarcoma and 7,5 for chordoma. Median time to local recurrence and distant metastasis was 1,2 years for high-grade osteosarcoma and 1,5 years for Ewing sarcoma. For high-grade osteosarcoma with localized disease at presentation, 0.09 new distant metastatic events per patient per year were seen after five years of follow-up with 11,1 patients needed to follow-up for any event. Five-year overall survival was 60,0% for high-grade chondrosarcoma, 50,0% for high-grade osteosarcoma, 45,3% for Ewing sarcoma and 71,4% for chordoma.

Conclusions: This nationwide study shows a plateau in local recurrences and distant metastatic events after four years of treatment for patients with high-grade osteosarcoma and Ewing sarcoma. Due to a lack of reliable evidence however, we were not able to provide additional guidance on follow-up intervals and duration. Collaborative research with larger groups is needed in order to provide a solid scientific recommendation for follow-up in the heterogenous patient population with bone sarcoma.

Keywords: ACT, Atypical Cartilaginous Tumour; Chondrosarcoma; DFI, Disease-Free Interval; Ewing sarcoma; Follow-up; NCR, Netherlands Cancer Registry; NOS, Not Otherwise Specified; Osteosarcoma; PALGA, Dutch Pathology Network.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Flowchart for inclusion.
Fig. 2a
Fig. 2a
Time to Local Recurrence in localized disease for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and Chordoma.
Fig. 2b
Fig. 2b
Time to Distant Metastasis in localized disease for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and Chordoma.
Fig. 3a
Fig. 3a
Competing risk analysis for local recurrence free survival for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and chordoma.
Fig. 3b
Fig. 3b
Competing risk analysis for distant metastasis free survival for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and chordoma.
Fig. 4
Fig. 4
Overall survival for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and chordoma.
See this image and copyright information in PMC

References

    1. Anninga J.K., Gelderblom H., Fiocco M., Kroep J.R., Taminiau A.H., Hogendoorn P.C., Egeler R.M. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur. J. Cancer. 2011;47:2431–2445. doi: 10.1016/j.ejca.2011.05.030. - DOI - PubMed
    1. van Oosterwijk J.G., Anninga J.K., Gelderblom H., Cleton-Jansen A.M., Bovee J.V. Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol. Oncol. Clin. North Am. 2013;27:1021–1048. doi: 10.1016/j.hoc.2013.07.012. - DOI - PubMed
    1. Gelderblom H., Hogendoorn P.C., Dijkstra S.D., van Rijswijk C.S., Krol A.D., Taminiau A.H., Bovee J.V. The clinical approach towards chondrosarcoma. Oncologist. 2008;13:320–329. doi: 10.1634/theoncologist.2007-0237. - DOI - PubMed
    1. Duchman K.R., Gao Y., Miller B.J. Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39:189–195. doi: 10.1016/j.canep.2014.12.012. - DOI - PubMed
    1. Duchman K.R., Gao Y., Miller B.J. Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database. Cancer Epidemiol. 2015;39:593–599. doi: 10.1016/j.canep.2015.05.001. - DOI - PubMed

LinkOut - more resources